BIM Stock Analysis: Biomerieux | PA
Diagnostics & Research | PA, France | Market Cap: 9.427m EUR | 12M Return: -26.3% | FR0013280286 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.5M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
bioMérieux S.A. is a French in vitro diagnostics (IVD) company that develops, manufactures, and markets diagnostic solutions for infectious diseases across more than 150 countries. The company operates through two segments: Clinical Applications, serving hospital and clinical laboratory customers, and Industrial Applications, serving sectors such as food safety, pharmaceuticals, and cosmetics. Its broad product portfolio spans culture media, automated identification and antimicrobial susceptibility testing (AST) systems, blood culture systems, multiplex PCR platforms, mass spectrometry, rapid AST solutions, and bioinformatics software for clinical decision support.
Key branded platforms include CHROMID chromogenic culture media, BACT/ALERT VIRTUO for blood culturing, BIOFIRE and BIOFIRE SPOTFIRE PCR systems, the VITEK family (VITEK MS, VITEK 2, VITEK REVEAL) for identification and AST, and VIDAS for immunoassay-based testing, along with industrial-focused lines such as GENE-UP, TEMPO, and BIOBALL. Founded in 1963 and headquartered in Marcy-lÉtoile, France, the company was formerly known as B-D Mérieux and operates as a subsidiary of Institut Mérieux SA, the holding entity of the broader Mérieux family group active in diagnostics and vaccines.
- BIOFIRE panel sales accelerate clinical applications revenue growth
- Industrial microbiology demand stabilizes amid food safety regulation
- IVDR compliance costs pressure European diagnostic margins
| Net Income: 462.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.10 > 1.0 |
| NWC/Revenue: 36.78% < 20% (prev 44.97%; Δ -8.19% < -1%) |
| CFO/TA 0.16 > 3% & CFO 907.6m > Net Income 462.4m |
| Net Debt (-81.1m) to EBITDA (917.1m): -0.09 < 3 |
| Current Ratio: 2.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.4m) vs 12m ago -0.18% < -2% |
| Gross Margin: 52.04% > 18% (prev 55.64%; Δ -3.60% > 0.5%) |
| Asset Turnover: 72.16% > 50% (prev 52.71%; Δ 19.45% > 0%) |
| Interest Coverage Ratio: 30.27 > 6 (EBIT TTM 478.3m / Interest Expense TTM 15.8m) |
| A: 0.26 (Total Current Assets 2.60b - Total Current Liabilities 1.13b) / Total Assets 5.69b |
| B: 0.04 (Retained Earnings 226.1m / Total Assets 5.69b) |
| C: 0.09 (EBIT TTM 478.3m / Avg Total Assets 5.53b) |
| D: 3.08 (Book Value of Equity 4.30b / Total Liabilities 1.39b) |
| Altman-Z'' = 5.64 = AAA |
| DSRI: 0.99 (Receivables 962.1m/688.4m, Revenue 3.99b/2.83b) |
| GMI: 1.07 (GM 55.64% / 52.04%) |
| AQI: 0.87 (AQ_t 0.24 / AQ_t-1 0.28) |
| SGI: 1.41 (Revenue 3.99b / 2.83b) |
| TATA: -0.08 (NI 462.4m - CFO 907.6m) / TA 5.69b) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at EUR 83.20 with a total of 201,378 shares traded. Over the past week, the price has changed by +8.40%, over one month by +16.04%, over three months by +16.12% and over the past year by -26.27%.
Current recommended Stop Loss: 80.70 (which is 3% or 1.3 ATR below the current price).
Biomerieux has no consensus analysts rating.
P/E Trailing = 20.5385
P/E Forward = 16.6113
P/S = 2.3623
P/B = 2.0063
P/EG = 1.6949
Revenue TTM = 3.99b EUR
EBIT TTM = 478.3m EUR
EBITDA TTM = 917.1m EUR
Long Term Debt = 66.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 233.2m EUR (from shortTermDebt, last quarter)
Debt = 576.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 154.8m
Net Debt = -81.1m EUR (calculated: Debt 576.6m - CCE 657.7m)
Enterprise Value = 9.35b EUR (9.43b + Debt 576.6m - CCE 657.7m)
Interest Coverage Ratio = 30.27 (Ebit TTM 478.3m / Interest Expense TTM 15.8m)
EV/FCF = 15.96x (Enterprise Value 9.35b / FCF TTM 585.5m)
FCF Yield = 6.26% (FCF TTM 585.5m / Enterprise Value 9.35b)
FCF Margin = 14.67% (FCF TTM 585.5m / Revenue TTM 3.99b)
Net Margin = 11.59% (Net Income TTM 462.4m / Revenue TTM 3.99b)
Gross Margin = 52.04% ((Revenue TTM 3.99b - Cost of Revenue TTM 1.91b) / Revenue TTM)
Gross Margin QoQ = 55.18% (prev 49.00%)
Tobins Q-Ratio = 1.64 (Enterprise Value 9.35b / Total Assets 5.69b)
Interest Expense / Debt = 2.74% (Interest Expense 15.8m / Debt 576.6m)
Taxrate = 23.89% (145.0m / 607.0m)
NOPAT = 364.0m (EBIT 478.3m * (1 - 23.89%))
Current Ratio = 2.30 (Total Current Assets 2.60b / Total Current Liabilities 1.13b)
Debt / Equity = 0.13 (Debt 576.6m / totalStockholderEquity, last quarter 4.30b)
Debt / EBITDA = -0.09 (Net Debt -81.1m / EBITDA 917.1m)
Debt / FCF = -0.14 (Net Debt -81.1m / FCF TTM 585.5m)
Total Stockholder Equity = 4.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.36% (Net Income 462.4m / Total Assets 5.69b)
RoE = 11.18% (Net Income TTM 462.4m / Total Stockholder Equity 4.13b)
RoCE = 11.39% (EBIT 478.3m / Capital Employed (Equity 4.13b + L.T.Debt 66.2m))
RoIC = 7.91% (NOPAT 364.0m / Invested Capital 4.60b)
WACC = 6.16% (E(9.43b)/V(10.0b) * Re(6.41%) + D(576.6m)/V(10.0b) * Rd(2.74%) * (1-Tc(0.24)))
Discount Rate = 6.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -6.13 | Cagr: -0.05%
[DCF] Terminal Value 77.97% ; FCFF base≈527.1m ; Y1≈604.2m ; Y5≈889.2m
[DCF] Fair Price = 114.4 (EV 13.4b - Net Debt -81.1m = Equity 13.5b / Shares 117.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 9.04 | Revenue CAGR: 1.68% | SUE: 1.12 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.34 | Chg30d=-0.12% | Revisions=-50% | GrowthEPS=-6.5% | GrowthRev=+1.3%
EPS next Year (2027-12-31): EPS=4.66 | Chg30d=-0.21% | Revisions=+17% | GrowthEPS=+7.3% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -22% (up=2, down=4)